Alster T S
Washington Institute of Dermatologic Laser Surgery, Washington, DC 20037, USA.
Lasers Surg Med. 1999;24(2):87-92. doi: 10.1002/(sici)1096-9101(1999)24:2<87::aid-lsm3>3.0.co;2-p.
Several erbium:YAG lasers are currently available for cutaneous laser resurfacing. Although different laser systems are purported to produce equivalent laser energies to produce similar laser-tissue interactions, no comparative clinical or histologic studies have been performed to objectively demonstrate their relative efficacies.
The purpose of the present study was to examine the in vivo clinical and histopathologic effects of six different erbium:YAG resurfacing lasers.
A blinded, prospective study using six different erbium lasers (Candela, Continuum Biomedical, HGM, MDLT, SEO, Sharplan/ESC) was performed. The facial halves of 12 patients were randomly resurfaced with one of the six laser systems by using an identical laser technique at 5.0 J/cm2. Intraoperative skin biopsies were obtained after each of three laser passes in two patients for blinded histologic determination of tissue ablation level and presence of residual thermal damage. Clinical assessments of reepithelialization rates, severity and duration of erythema, side effects, and degree of clinical improvement were made at 0.5, 1, 2, 4, 12, 26, and 52 weeks postoperatively.
Irrespective of the erbium laser system used, complete reepithelialization typically occurred at 0.5 weeks and resolution of erythema was noted within 1-2 weeks postoperatively. A mean clinical improvement of 50% was observed, with photodamaged skin showing greater improvement than scarred skin. The most common postoperative side effect was hyperpigmentation, with all affected patients having either darker skin tones or preceding dermal inflammation. Three laser passes were needed to effect total epidermal ablation when using any one of the erbium:YAG systems.
Equivalent clinical and histologic results were seen after each of the six erbium:YAG lasers studied. Erbium:YAG laser resurfacing can be used to significantly improve mild cutaneous photodamage and atrophic scars.
目前有几种铒钇铝石榴石激光可用于皮肤激光换肤。尽管不同的激光系统据称能产生等效的激光能量以产生相似的激光与组织相互作用,但尚未进行比较性临床或组织学研究来客观证明它们的相对疗效。
本研究的目的是检验六种不同铒钇铝石榴石换肤激光的体内临床和组织病理学效应。
采用六种不同的铒激光(坎德拉、连续生物医学、HGM、MDLT、SEO、沙普兰/ESC)进行了一项双盲前瞻性研究。12名患者的面部两侧通过使用相同的激光技术,以5.0 J/cm²的能量随机用六种激光系统之一进行换肤。在两名患者中,每次激光照射三次后进行术中皮肤活检,以双盲方式进行组织学测定组织消融水平和是否存在残余热损伤。在术后0.5、1、2、4、12、26和52周对上皮再形成率、红斑的严重程度和持续时间、副作用以及临床改善程度进行临床评估。
无论使用哪种铒激光系统,上皮通常在0.5周完全再形成,术后1 - 2周内红斑消退。观察到平均临床改善率为50%,光损伤皮肤的改善比瘢痕皮肤更大。最常见的术后副作用是色素沉着,所有受影响患者的肤色较深或之前有皮肤炎症。使用任何一种铒钇铝石榴石系统时,需要三次激光照射才能实现表皮完全消融。
在所研究的六种铒钇铝石榴石激光中,每种激光都观察到了等效的临床和组织学结果。铒钇铝石榴石激光换肤可用于显著改善轻度皮肤光损伤和萎缩性瘢痕。